[Ip-health] KEI Appeals NIH/NCI Decision to Proceed with License of CD30 CAR T technology to Gilead/Kite

Andrew Goldman andrew.goldman at keionline.org
Tue Feb 27 07:20:16 PST 2018


KEI has appealed the NIH/NCI decision to proceed with the proposed
exclusive license of anti-CD30 CAR T technology to Gilead.

We have posted a blog on this appeal here: https://www.keionline.org/26686

The appeal itself is available here:
https://www.keionline.org/wp-content/uploads/2018/02/Appeal-of-NIH-NCI-decision-to-proceed-with-anti-CD30-license-to-Kite-26Feb2018.pdf

However, NIH wrote to say that they would reject the appeal even before it
was filed. We submitted the appeal formally, and requested that they
reconsider that decision.

--
Andrew S. Goldman
Counsel, Policy and Legal Affairs
Knowledge Ecology International
andrew.goldman at keionline.org // www.twitter.com/ASG_KEI
tel.: +1.202.332.2670 <(202)%20332-2670>
www.keionline.org


More information about the Ip-health mailing list